Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation

AAPS PharmSciTech

Volumn 12, Issue 4, 2011, Pages 1077-1086

  Khan, Furquan Nazimuddin ^a   Dehghan, Mohamed Hassan G ^a  

^a Y B CHAVAN COLLEGE OF PHARMACY   (India)

Author keywords

atorvastatin calcium; bioavailibility; floating tablets; gastro retention; stabilization

Indexed keywords

ATORVASTATIN; BICARBONATE; CALCIUM; CROSCARMELLOSE SODIUM; DOCUSATE SODIUM; HYDROXYPROPYLMETHYLCELLULOSE; LACTONE; MACROGOL; MAGNESIUM STEARATE; MANNITOL;

ANIMAL EXPERIMENT; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; EXPERIMENTAL RABBIT; FACTORIAL DESIGN; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; TABLET; VISCOSITY; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CARBOXYMETHYLCELLULOSE SODIUM; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DIOCTYL SULFOSUCCINIC ACID; DRUG COMPOUNDING; DRUG STABILITY; EXCIPIENTS; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MANNITOL; METHYLCELLULOSE; POLYETHYLENE GLYCOLS; POWDER DIFFRACTION; PYRROLES; RABBITS; REGRESSION ANALYSIS; SODIUM BICARBONATE; SOLUBILITY; STEARIC ACIDS; STOMACH; TABLETS; TECHNOLOGY, PHARMACEUTICAL; VISCOSITY; WATER; X-RAY DIFFRACTION;

EID: 83555173187     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9673-3     Document Type: Article

References (22)

1. Kerc J, inventor. Stable Pharmaceutical formulation comprising a HMG CoA reductase inhibitor. US Patent Application, 22 Oct 2009.
2. Kerc J, Salobir M, Bavec S, inventors. Atorvastatin calcium in a pharmaceutical form composition thereof and pharmaceutical formulation comprising atorvastatin calcium. US Patent 7030151, 18 April 2006.
3. AS Kearny LF Crawford SC Mehta GW Radebaugh 1993 The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981 Pharm Res 10 1461 1465 10.1023/A:1018923325359 (Pubitemid 23302663)
4. M Ishigami T Honda W Takashi 2001 A comparison of the effects of 3-hydroxy-3- methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro Drug Metab Dispos 29 282 288 11181496 1:CAS:528:DC%2BD3MXhsVKitLY%3D (Pubitemid 32179528)
5. Mills N, Muhammad NA, Weiss J, Nesbitt RU, inventors. Stable oral CI-981 formulation and process for preparing same.US Patent 6126971, 3 Oct 2000.
6. CR Palem S Patel BV Pokharkar 2009 Solubility and stability enhancement of atorvastatin by cyclodextrin complexation. PDA J Pharm Sci Technol 63 217 225 1:CAS:528:DC%2BD1MXhs1WiurzJ
7. Laxminarayan J. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor. US patent application 20090247603, 01 Oct 2009.
8. RS Hai KZ Ming 2006 Preparation and evaluation of self-micro emulsifying drug delivery systems (SMEDDS) containing atorvastatin J Pharm Pharmacol 58 1183 1191
9. PJ Kadu SS Kushare DD Thacker SG Gattani 2011 Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS) Pharm Dev Tech 16 65 74 10.3109/10837450903499333 1:CAS:528:DC%2BC3MXit1KhtA%3D%3D
10. H Lennernas 2003 Clinical Pharmacokinetics of atorvastatin Clin Pharmacokinet 42 1141 1160 14531725 10.2165/00003088-200342130-00005 (Pubitemid 37357650)
11. SD Brijesh FA Avani MP Madhabhai 2004 Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation AAPS PharmSciTech 5 34
12. The British Pharmacopoeia. British Pharmacopoeia Commission. London: HMSO; 2007 (electronic version).
13. M Rosa H Zia T Rhodes 1994 Dosing and testing in-vitro of a bioadhesive and floating drug delivery system for oral application Int J Pharm 105 64 70
14. P Kocbek S Baumgartner J Kristi 2006 Preparation and evaluation of nanosuspensions for enhancing dissolution of poorly soluble drugs Int J Pharm 312 179 186 16469459 10.1016/j.ijpharm.2006.01.008 1:CAS:528: DC%2BD28XisFeqtro%3D
15. D Skorda 2008 Kontoyannis C.G. Identification and quantitative determination of atorvastatin calcium polymorph in tablets using FT-Raman spectroscopy Talanta 74 1066 1070 18371751 10.1016/j.talanta.2007.07.030 1:CAS:528:DC%2BD1cXjtVyntg%3D%3D
16. BR Mathews 1999 Regulatory aspects of stability testing in Europe Drug Dev Ind Pharm 25 831 856 10.1081/DDC-100102245 (Pubitemid 29292916)
17. SR Parakh AV Gothoskar MTA Karad 2003 novel method for the study of water absorption rates by swellable matrices Pharm Tech. 5 40 48 (Pubitemid 37101903)
18. G Shete V Puri L Kumar AK Bansal 2010 Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples AAPS Pharm Sci Tech 11 598 609 10.1208/s12249-010-9419-7 1:CAS:528:DC%2BC3cXptVeqsbY%3D
19. T Higuchi 1963 Mechanism of sustained action medication J Pharm Sci 52 1145 1149 14088963 10.1002/jps.2600521210 1:CAS:528:DyaF2cXlt1Whsg%3D%3D
20. PL Ritger NA Peppas 1987 A simple equation for description of solute release. I. Fickian and non-fickian release from non-swellable devices in the form slabs, spheres, cylinder or discs J Control Release 5 23 36 10.1016/0168-3659(87)90034-4 1:CAS:528:DyaL2sXkvVeku7o%3D (Pubitemid 17106643)
21. Bolton S. Pharmaceutical statistics, practical and clinical applications. 2nd ed. New York: Marcel Dekker; 1990.
22. M Kracuna A Kocijana A Bastardaa A Graheka J Plavecb D Kocjanb 2009 Isolation and structure determination of oxidative degradation products of atorvastatin J Pharm Biomed Anal 50 729 736 10.1016/j.jpba.2009.06.008